MusclePharm Q4 revenues off 13%, net loss widens four-fold; only $1M cash on hand

|About: MusclePharm Corp. (MSLP)|By:, SA News Editor

MusclePharm (OTCQB:MSLP) Q4 results ($M): Net Revenues: 32.7 (-12.8%); Gross Profit: 25.1 (-9.7%); Operating Expenses: 23.9 (+52.2%); Operating Loss: (16.4) (-173.3%); Net Loss: (16.2) (-305.0%); Loss Per Share: (1.39) (-208.9%); Quick Assets: 1.0 (-81.5%); A/R: 16.6 (+21.2%); Inventory: 21.1 (+33.5%).

2015 Guidance: Net Sales: $210M - 220M; Gross Margin: 31 - 33%.

This was an ugly quarter for the supposed high flier. Revenue growth was negative, inventory backed up and expenses skyrocketed. With only $1M in the bank, the company won't be able to make payroll for long.

Profitability remains elusive. Best case for gross margin of 33% for this year won't be enough to make money. Gross margin for 2014 was 31.6% versus 29.9% the year before, a modest increase considering the aggressive top line growth.

Subscribe for full text news in your inbox